Identification
- Summary
Lurasidone is an atypical antipsychotic used to treat schizophrenia and depressive episodes associated with bipolar I disorder.
- Brand Names
- Latuda
- Generic Name
- Lurasidone
- DrugBank Accession Number
- DB08815
- Background
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Lurasidone (DB08815)
- Weight
- Average: 492.676
Monoisotopic: 492.255897106 - Chemical Formula
- C28H36N4O2S
- Synonyms
- Lurasidona
- Lurasidone
- Lurasidonum
- External IDs
- SM-13496
Pharmacology
- Indication
Lurasidone is indicated for the treatment of schizophrenia in patients ≥13 years old.3 It is also indicated as a monotherapy for the treatment of bipolar depression in patients ≥10 years old, or in combination with lithium or valproate for the treatment of bipolar depression in adults.3
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Adjunct therapy in management of Depression, bipolar •••••••••••• ••••• •••••• Adjunct therapy in management of Depression, bipolar •••••••••••• ••••• •••••• Management of Depression, bipolar •••••••••••• •••••• ••••••••• •••••• Management of Schizophrenia •••••••••••• ••••••••••• ••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Lurasidone is a benzothiazol derivative that is an antagonist and binds with high affinity to Dopamine-2 (D2) (Ki = 0.994 nM), 5-HT2A (Ki = 0.47 nM) receptors, and 5-HT7 receptors (Ki = 0.495 nM). It also binds with moderate affinity to alpha-2C adrenergic receptors (Ki = 10.8 nM) and is a partial agonist at 5-HT1A receptors (Ki = 6.38 nM). Its actions on histaminergic and muscarinic receptors are negligible.
- Mechanism of action
Lurasidone is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and dopamine activity) to improve cognition. It is thought that antagonism of serotonin receptors can improve negative symptoms of psychoses and reduce the extrapyramidal side effects that are often associated with typical antipsychotics.
Target Actions Organism ADopamine D2 receptor antagonistHumans A5-hydroxytryptamine receptor 2A antagonistHumans U5-hydroxytryptamine receptor 7 antagonistHumans U5-hydroxytryptamine receptor 1A antagonistHumans UAlpha-2C adrenergic receptor antagonistHumans UAlpha-2A adrenergic receptor Not Available Humans - Absorption
Lurasidone is readily absorbed and quickly reaches maximal concentrations (Cmax) within 1-4 hours. When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours. This occurs regardless of fat or caloric content.
Bioavailability = 9-19%.- Volume of distribution
6173 L
- Protein binding
~99% bound to serum proteins.
- Metabolism
Lurasidone is metabolized by CYP3A4 in which its major active metabolite is referred to as ID-14283 (25% of parent exposure). Its two minor metabolites are referred to as ID14326 and ID11614 which make up 3% and 1% of parent exposure respectively. Its two non-active metabolites are referred to as ID-20219 and ID-20220.
Hover over products below to view reaction partners
- Route of elimination
Urine (~9%) and feces (~80%)
- Half-life
40 mg dose= 18 hours 120 mg - 160 mg dose = 29-37 hours
- Clearance
3902 mL/min
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Lurasidone is combined with 1,2-Benzodiazepine. Abametapir The serum concentration of Lurasidone can be increased when it is combined with Abametapir. Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Lurasidone. Acebutolol Lurasidone may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when Aceclofenac is combined with Lurasidone. - Food Interactions
- Avoid alcohol. The effects of alcohol could be made worse while taking Lurasidone.
- Avoid grapefruit products. Grapefruit and grapefruit juice may affect the amount of Lurasidone in your blood.
- Take with food. The manufacturer recommends co-administration with at least 350 calories.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Lurasidone hydrochloride O0P4I5851I 367514-88-3 NEKCRUIRPWNMLK-SCIYSFAVSA-N - Product Images
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Latuda Tablet 60 mg Oral Sunovion 2014-03-14 Not applicable Canada 
Latuda Tablet, film coated 37 mg Oral Aziende Chimiche Riunite Angelini Francesco S.P.A. 2020-12-16 Not applicable EU 
Latuda Tablet 40 mg Oral Sunovion 2012-09-06 Not applicable Canada Latuda Tablet, film coated 18.5 mg Oral Aziende Chimiche Riunite Angelini Francesco S.P.A. 2020-12-16 Not applicable EU Latuda Tablet, film coated 120 mg/1 Oral Sumitomo Pharma America, Inc. 2012-04-26 Not applicable US 
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Auro-lurasidone Tablet 120 mg Oral Auro Pharma Inc 2023-10-30 Not applicable Canada Auro-lurasidone Tablet 40 mg Oral Auro Pharma Inc 2023-10-30 Not applicable Canada Auro-lurasidone Tablet 80 mg Oral Auro Pharma Inc 2023-10-30 Not applicable Canada Auro-lurasidone Tablet 20 mg Oral Auro Pharma Inc 2023-10-30 Not applicable Canada Auro-lurasidone Tablet 60 mg Oral Auro Pharma Inc 2023-10-30 Not applicable Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image LURALEP Lurasidone (40 mg) + Lurasidone (80 mg) Tablet, coated Oral MSN LABS AMERICAS S A S 2020-12-09 2025-12-29 Colombia 
LURALEP Lurasidone (40 mg) + Lurasidone (80 mg) Tablet, coated Oral MSN LABS AMERICAS S A S 2020-12-09 2025-12-29 Colombia
Categories
- ATC Codes
- N05AE05 — Lurasidone
- Drug Categories
- Adrenergic Agents
- Adrenergic alpha-2 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Adrenergic Antagonists
- Agents that produce hypertension
- Antidepressive Agents
- Antipsychotic Agents
- Antipsychotic Agents (Second Generation [Atypical])
- Central Nervous System Agents
- Central Nervous System Depressants
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Substrates
- Dopamine Agents
- Dopamine Antagonists
- Dopamine D2 Receptor Antagonists
- Heterocyclic Compounds, Fused-Ring
- Hyperglycemia-Associated Agents
- Indole Derivatives
- Isoindoles
- Nervous System
- Neurotoxic agents
- Neurotransmitter Agents
- Potential QTc-Prolonging Agents
- Psycholeptics
- Psychotropic Drugs
- QTc Prolonging Agents
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Serotonin 5-HT1 Receptor Antagonists
- Serotonin 5-HT1A Receptor Antagonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin 5-HT2A Receptor Antagonists
- Serotonin Agents
- Serotonin Receptor Antagonists
- Sulfur Compounds
- Thiazoles
- Tranquilizing Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- N-arylpiperazines
- Alternative Parents
- Aromatic monoterpenoids / Isoindolones / Benzothiazoles / Dialkylarylamines / N-alkylpiperazines / Aminothiazoles / Benzenoids / Pyrrolidine-2-ones / Imidolactams / N-substituted carboxylic acid imides show 11 more
- Substituents
- 1,2-benzothiazole / 1,2-thiazolamine / 2-pyrrolidone / Amine / Amino acid or derivatives / Aromatic heteropolycyclic compound / Aromatic monoterpenoid / Azacycle / Azole / Benzenoid show 29 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- N-arylpiperazine, dicarboximide, bridged compound, 1,2-benzisothiazole (CHEBI:70735)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 22IC88528T
- CAS number
- 367514-87-2
- InChI Key
- PQXKDMSYBGKCJA-CVTJIBDQSA-N
- InChI
- InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1
- IUPAC Name
- (1R,2S,6R,7S)-4-{[(1R,2R)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo[5.2.1.0^{2,6}]decane-3,5-dione
- SMILES
- [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O
References
- General References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [Article]
- Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. [Article]
- FDA Approved Drug Products: Latuda (lurasidone hydrochloride) oral tablets [Link]
- External Links
- KEGG Drug
- D04820
- PubChem Compound
- 213046
- PubChem Substance
- 175427100
- ChemSpider
- 184739
- BindingDB
- 85222
- 1040028
- ChEBI
- 70735
- ChEMBL
- CHEMBL1237021
- ZINC
- ZINC000003927822
- PharmGKB
- PA166129557
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Lurasidone
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Schizophrenia 1 4 Completed Basic Science Depression, Bipolar 1 4 Completed Treatment Psychosis 1 4 Completed Treatment Schizoaffective Disorders / Schizophrenia 1 4 Completed Treatment Schizophrenia 3
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 120 mg Tablet Oral 20 mg Tablet Oral 40 mg Tablet Oral 60 mg Tablet Oral 80 mg Tablet, film coated Oral 120 mg/1 Tablet, film coated Oral 18.5 MG Tablet, film coated Oral 20 mg/1 Tablet, film coated Oral 37 MG Tablet, film coated Oral 40 mg/1 Tablet, film coated Oral 60 mg/1 Tablet, film coated Oral 74 MG Tablet, film coated Oral 80 mg/1 Tablet, film coated Oral 20 mg Tablet, coated Oral 20 mg Tablet, film coated Oral 120 mg Tablet, film coated Oral 60 mg Tablet, coated Oral Tablet Oral 120 mg/1 Tablet Oral 20 mg/1 Tablet Oral 40 mg/1 Tablet Oral 60 mg/1 Tablet Oral 80 mg/1 Tablet, coated Oral 120 mg/1 Tablet, coated Oral 20 mg/1 Tablet, coated Oral 40 mg/1 Tablet, coated Oral 60 mg/1 Tablet, coated Oral 80 mg/1 Tablet, coated Oral 40 mg Tablet, film coated Oral 40 mg Tablet, coated Oral 80 mg Tablet, film coated Oral 80 mg - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US9174975 Yes 2015-11-03 2026-12-25 US US9259423 Yes 2016-02-16 2031-11-23 US US8729085 Yes 2014-05-20 2026-11-26 US US5532372 Yes 1996-07-02 2019-01-02 US US8883794 Yes 2014-11-11 2026-11-26 US USRE45573 Yes 2015-06-23 2025-12-23 US US9555027 No 2017-01-31 2026-05-26 US US9815827 No 2017-11-14 2024-02-20 US US9827242 No 2017-11-28 2031-05-23 US US9907794 Yes 2018-03-06 2026-11-26 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00789 mg/mL ALOGPS logP 5.25 ALOGPS logP 4.56 Chemaxon logS -4.8 ALOGPS pKa (Strongest Basic) 8.5 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 56.75 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 139.33 m3·mol-1 Chemaxon Polarizability 56.26 Å3 Chemaxon Number of Rings 7 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9907 Caco-2 permeable + 0.5257 P-glycoprotein substrate Substrate 0.6029 P-glycoprotein inhibitor I Inhibitor 0.6713 P-glycoprotein inhibitor II Inhibitor 0.73 Renal organic cation transporter Inhibitor 0.5487 CYP450 2C9 substrate Non-substrate 0.7897 CYP450 2D6 substrate Substrate 0.8918 CYP450 3A4 substrate Substrate 0.5922 CYP450 1A2 substrate Non-inhibitor 0.677 CYP450 2C9 inhibitor Inhibitor 0.6714 CYP450 2D6 inhibitor Non-inhibitor 0.8292 CYP450 2C19 inhibitor Inhibitor 0.7439 CYP450 3A4 inhibitor Non-inhibitor 0.7835 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.8126 Ames test Non AMES toxic 0.6477 Carcinogenicity Non-carcinogens 0.8986 Biodegradation Not ready biodegradable 0.9959 Rat acute toxicity 2.4051 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6636 hERG inhibition (predictor II) Inhibitor 0.5858
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-002f-0005900000-b0e836e7af7519880372 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-0000900000-132d601f4d78dc89277a Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00mo-1319700000-23e1e4b6716f0386d81a Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-002f-0106900000-db69a1ca7f69e95b684b Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-03gl-0903400000-c785d3bf23b8a173a961 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-004m-9316500000-fba8e77b044d2ef77796 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 206.13554 predictedDeepCCS 1.0 (2019) [M+H]+ 208.05267 predictedDeepCCS 1.0 (2019) [M+Na]+ 213.84412 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Potassium channel regulator activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- DRD2
- Uniprot ID
- P14416
- Uniprot Name
- D(2) dopamine receptor
- Molecular Weight
- 50618.91 Da
References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Virus receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
- Gene Name
- HTR2A
- Uniprot ID
- P28223
- Uniprot Name
- 5-hydroxytryptamine receptor 2A
- Molecular Weight
- 52602.58 Da
References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Serotonin receptor activity
- Specific Function
- This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
- Gene Name
- HTR7
- Uniprot ID
- P34969
- Uniprot Name
- 5-hydroxytryptamine receptor 7
- Molecular Weight
- 53554.43 Da
References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
- Gene Name
- HTR1A
- Uniprot ID
- P08908
- Uniprot Name
- 5-hydroxytryptamine receptor 1A
- Molecular Weight
- 46106.335 Da
References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Protein homodimerization activity
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
- Gene Name
- ADRA2C
- Uniprot ID
- P18825
- Uniprot Name
- Alpha-2C adrenergic receptor
- Molecular Weight
- 49521.585 Da
References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Thioesterase binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
- Gene Name
- ADRA2A
- Uniprot ID
- P08913
- Uniprot Name
- Alpha-2A adrenergic receptor
- Molecular Weight
- 48956.275 Da
References
- Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
Drug created at July 24, 2011 17:04 / Updated at February 20, 2024 23:55